Protagonist Therapeutics Releases Promising Data on Icotrokinra

Protagonist Therapeutics recently unveiled new data on icotrokinra, an investigational targeted oral peptide, highlighting significant findings in ulcerative colitis and plaque psoriasis treatments. The Phase 2b ANTHEM-UC study indicated that 31.7% of patients achieved clinical remission in ulcerative colitis at Week 28.

Moreover, the ICONIC-TOTAL study showed that icotrokinra achieved site-specific skin clearance rates of 72% and 85% in scalp and genital psoriasis, respectively, by Week 52. These results bolster support for Phase 3 development plans.

These findings were presented at the American College of Gastroenterology and Fall Clinical Dermatology Conferences, showcasing icotrokinra's potential as a durable and effective treatment for inflammatory diseases.